2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR

GCGR

Glucagon Receptor

GCGR

Related Products

PDF 0.98 MB

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1224
    HAEGTFTSDVS
    		98.62%
    HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.
    HAEGTFTSDVS
  • HY-P10341
    ZP3022
    		Agonist 98.00%
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research.
    ZP3022
  • HY-119739
    Skyrin
    		Antagonist
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells.
    Skyrin
  • HY-P11237
    Enicepatide
    		Agonist
    Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
    Enicepatide
  • HY-147622
    GLP-1R agonist 9
    		Agonist
    GLP-1R agonist 9 (Compound 96) is a GLP-1R agonist with EC50 values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively.
    GLP-1R agonist 9
  • HY-10036
    Glucagon receptor antagonist-1
    		Antagonist 98.65%
    Glucagon receptor antagonist-1 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-1
  • HY-P3506B
    Retatrutide acetate
    		Agonist
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity.
    Retatrutide acetate
  • HY-108795B
    [Gly8]-GLP-1(7-37) acetate
    		Agonist 99.11%
    [Gly8]-GLP-1(7-37) acetate is a derivative of GLP-1 containing alanine-to-glycine substitution at positions 8.
    [Gly8]-GLP-1(7-37) acetate
  • HY-P1227
    SDV-Exendin-3/4
    SDV-Exendin-3/4 is a 32-amino acid peptide.
    SDV-Exendin-3/4
  • HY-P1229
    FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
    		98.01%
    FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.
    FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
  • HY-P1223
    Exendin-3/4 (59-86)
    		98.19%
    Exendin-3/4 (59-86) is a Exendin-4 peptide derivative.
    Exendin-3/4 (59-86)
  • HY-P1225
    {Val1}-Exendin-3/4
    		99.45%
    {Val1}-Exendin-3/4 is the first N-terminal 1-28 residues of Exendin-4 peptide.
    {Val1}-Exendin-3/4
  • HY-144035
    GLP-1R agonist 4
    		Agonist 98.26%
    GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc.
    GLP-1R agonist 4
  • HY-142162A
    (S,R)-LSN3318839
    		Control 98.25%
    (S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar.
    (S,R)-LSN3318839
  • HY-P11274
    Zenagamtide
    		Agonist
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
    Zenagamtide
  • HY-128781
    Glucagon receptor antagonist-5
    		Antagonist
    Glucagon receptor antagonist-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonist-5 has potential for the treatment of type 2 diabetes mellitus (T2DM).
    Glucagon receptor antagonist-5
  • HY-112668B
    Retagliptin hydrochloride
    Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1).
    Retagliptin hydrochloride
  • HY-172811
    DA-302168S
    		Agonist
    DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study.
    DA-302168S
  • HY-P3469
    Dasiglucagon
    		Agonist
    Dasiglucagon is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research.
    Dasiglucagon
  • HY-138996
    GLP-1 receptor agonist 8
    		Agonist
    GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17).
    GLP-1 receptor agonist 8
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity